Grant Hardan
Optometrist · Spokane, WANPI 1851603955
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,482 of the $5,251 with a category attached, or 85.3%. 14 manufacturers reported payments, led by Alcon at 41.4% of the total. Among optometrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $36.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Sun Pharmaceutical Industries Inc.$801
- AbbVie$790
- Bausch & Lomb Americas Inc.$324
- Tarsus Pharmaceuticals, Inc.$284
- Bausch & Lomb, A Division Of Bausch Health US, LLC$190
- plus $687 from 8 others
What the payments were for
- Speaking & faculty fees$75014%
- Food & beverage$4,48285%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 51 | $2,175 |
| Sun Pharmaceutical Industries Inc. | 32 | $801 |
| AbbVie(2 entities) | 22 | $790 |
| Bausch & Lomb Americas Inc. | 11 | $324 |
| Tarsus Pharmaceuticals, Inc. | 5 | $284 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $190 |
| Novartis | 5 | $184 |
| ABB Con-cise Optical Group LLC | 2 | $139 |
| Coopervision Inc. | 1 | $122 |
| Johnson & Johnson Vision Care, Inc. | 5 | $114 |
| Oyster Point Pharma, Inc. | 3 | $52 |
| Shire North American Group Inc | 2 | $37 |
| Harrow Eye, LLC | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES TOTAL1$750
- Precision 1$750
- XDEMVY$250
- BIOTRUE$125
- ULTRA$125
- BIOTRUE ONE DAY$125
- TRYPTYR$125
- Rocklatan$125
- Rhopressa$125
- SIMBRINZA$125
- XIIDRA$125
- MyDay Contact Lens$122
- VUITY$121
- RESTASIS$114
- CEQUA$101
How this compares
$5,251 in reported general payments places this provider in the 95th percentile of 1,267 optometrist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 64 | $66,123 |
| VevyeCyclosporine | 15 | $20,574 |
| LumiganBimatoprost | 19 | $14,489 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $8,039 |
| Cyclosporine | 16 | $7,850 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $3,860 |
| Alphagan PBrimonidine Tartrate | 17 | $3,834 |
| Latanoprost | 83 | $1,057 |
| Brimonidine Tartrate | 24 | $729 |
| Timolol Maleate | 49 | $697 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $456 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 26 | $259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $790 | $92,486114 claims |
| Harrow Eye, LLCVevye | $21 | $20,57415 claims |
| AlconSimbrinza | $2,175 | $3,86014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,267 optometrist providers in Washington.
Other optometrist in Spokane
- David KadingKirkland$397K
- Peter BergenskeOtis Orchards$355K
- Casey ClaypoolSpokane Valley$323K
- Charles ClaytonBellevue$195K
- Herminder BoparaiBellevue$131K
- Rajiv PatelVancouver$118K
- Alan ChousTacoma$115K
- Roya HabibiSeattle$109K
- Bryan HeitmeyerKent$67K
- Kevin OsborneMoses Lake$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.